Payment overview · 2025
General Payments
$927.01
50 reported records · 12 companies
Healthcare provider profile · identity verified
Muzaffar Rahat, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MERIDIAN, MS · NPI 1336145762
Verified facts
What the public records show
CMS Open Payments records show Muzaffar Rahat, M.D. received $927.01 in general payments during 2025 across 50 reported records.
Novo Nordisk Inc accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $229.68 | 24.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $181.45 | 19.6% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.45 | 8.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.45 | 8.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.54 | 8.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.81 | 7.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.23 | 6.9% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $44.57 | 4.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.84 | 3.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.65 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.48 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.86 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $894.74 | 49 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $161.34 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $107.18 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $98.07 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $82.45 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.81 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.23 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.78 | 3 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| VANTA ADAPTIVESTIM Normalized: vanta adaptivestim |
Device | Medtronic, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 148 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 201 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
201 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 468 | 146 |
| Omeprazole | Omeprazole | 460 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 341 | 115 |
| Gabapentin | Gabapentin | 307 | 99 |
| Metformin Hcl | Metformin Hcl | 303 | 80 |
| Losartan Potassium | Losartan Potassium | 295 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 265 | 88 |
| Meloxicam | Meloxicam | 220 | 75 |
| Furosemide | Furosemide | 219 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 58 |
| Ozempic | Semaglutide | 201 | 23 |
| Lisinopril | Lisinopril | 190 | 52 |
| Sertraline Hcl | Sertraline Hcl | 172 | 45 |
| Carvedilol | Carvedilol | 160 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 61 |
| Eliquis | Apixaban | 148 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 42 |
| Montelukast Sodium | Montelukast Sodium | 147 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 44 |
| Simvastatin | Simvastatin | 141 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 44 |
| Tramadol Hcl | Tramadol Hcl | 136 | 29 |
| Azithromycin | Azithromycin | 131 | 90 |
| Allopurinol | Allopurinol | 124 | 41 |
| Glimepiride | Glimepiride | 123 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 49 |
| Prednisone | Prednisone | 121 | 64 |
| Amitriptyline Hcl | Amitriptyline Hcl | 118 | 30 |
| Celecoxib | Celecoxib | 117 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 42 |
| Trazodone Hcl | Trazodone Hcl | 105 | 31 |
| Donepezil Hcl | Donepezil Hcl | 102 | 33 |
| Buspirone Hcl | Buspirone Hcl | 99 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 33 |
| Jardiance | Empagliflozin | 98 | 19 |
| Farxiga | Dapagliflozin Propanediol | 88 | 22 |
| Metformin Hcl Er | Metformin Hcl | 87 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 17 |
| Levofloxacin | Levofloxacin | 68 | 51 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 14 |
| Memantine Hcl | Memantine Hcl | 60 | 25 |
| Atenolol | Atenolol | 59 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 15 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 14 |
| Linzess | Linaclotide | 54 | 14 |
| Clonidine Hcl | Clonidine Hcl | 53 | 19 |
| Ezetimibe | Ezetimibe | 51 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 49 | 17 |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 16 |
| Nifedipine Er | Nifedipine | 47 | 12 |
| Spironolactone | Spironolactone | 46 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 31 |
| Famotidine | Famotidine | 43 | 18 |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Colchicine | Colchicine | 38 | 20 |
| Nystatin | Nystatin | 38 | 30 |
| Brilinta | Ticagrelor | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | 12 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Novolog | Insulin Aspart | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Fluconazole | Fluconazole | 31 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 17 |
| Estradiol | Estradiol | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 24 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 15 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | 11 |
| Lactulose | Lactulose | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $927.01 · 50 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, GVOKE HYPOPEN, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VANTA ADAPTIVESTIM, Wegovy, ZAVZPRET, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error